studies

HEPATOLOGY, VOLUME 62, NUMBER 1 (SUPPL) AASLD ABSTRACTS 523A
64% with an average intensity of 1.7 + 0.9 (scale 1-4). Over
90% of participants were willing to donate biospecimens and
be contacted for clinical research. Conclusions: Participants in
the PSC Partners Registry are similar to other cohorts but are
majority female, more symptomatic, and are a resource for
future research.
for PBC, a clear and important unmet need persists, as corroborated
by variable UDCA response. The ongoing unmet need
for PSC is striking, despite widespread UDCA use, and in the
face of rising rates of transplantation for other liver diseases.
Table 1. Comparison of Confirmed versus Unconfirmed PSC
Cases
Disclosures:
Gregory T. Everson - Advisory Committees or Review Panels: Roche/Genentech,
Abbvie, Galectin, Boehringer-Ingelheim, Eisai, Bristol-Myers Squibb, HepC
Connection, BioTest, Gilead, Merck; Board Membership: HepQuant LLC, PSC
Partners, HepQuant LLC; Consulting: Abbvie, BMS, Gilead, Bristol-Myers Squibb;
Grant/Research Support: Roche/Genentech, Pharmassett, Vertex, Abbvie, Bristol-Myers
Squibb, Merck, Eisai, Conatus, PSC Partners, Vertex, Tibotec, GlobeImmune,
Pfizer, Gilead; Management Position: HepQuant LLC, HepQuant LLC;
Patent Held/Filed: Univ of Colorado; Speaking and Teaching: Abbvie, Gilead
Christopher L. Bowlus - Advisory Committees or Review Panels: Gilead Sciences,
Inc; Grant/Research Support: Gilead Sciences, Inc, Intercept Pharmaceuticals,
Bristol Meyers Squibb, Takeda, Lumena, Merck; Speaking and Teaching: Gilead
Sciences, Inc
The following authors have nothing to disclose: Rachel Gomel, Ricky Safer, Jesse
A. King, Estella M. Geraghty, Keith D. Lindor
631
Cholestatic liver disease and liver transplantation in the
UK: a twenty year review
Gwilym Webb 1,2 , James W. Ferguson 2 , David Jones 4 , James Neuberger
2,3 , Gideon Hirschfield 1,2 ; 1 NIHR Centre for Liver Research,
University of Birmingham, Birmingham, United Kingdom; 2 Hepatology,
Queen Elizabeth Hospital, Birmingham, United Kingdom;
3 NHS Blood and Transplant, Bristol, United Kingdom; 4 Newcastle
University, Newcastle, United Kingdom
Background: Primary biliary cirrhosis (PBC) and primary sclerosing
cholangitis (PSC) represent major indications for orthotopic
liver transplantation (OLT). Ursodeoxycholic acid (UDCA) has
been prescribed in the UK for most patients with PBC and PSC,
with consensus for efficacy only in PBC. Aim: To analyse transplant
listing and transplantation for PBC and PSC over the last
20 years of UK-wide practice. Results: We analysed national
transplant registry data for 1995 to 2014 inclusive. Records for
12,935 listings and 10,512 OLTs were reviewed. Listings for
all indications increased from 494 to 976/year (21.2±2.3/
year; r 2 =0.82; p